You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDS
DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDS
DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: LUNA INNOVATIONS INCORPORATED Topic: NIGMS
DESCRIPTION (provided by applicant): Mycotoxin is naturally occurring and is a toxic small molecule produced by fungi. These fungal toxins are representative of a large number of lipophilic agents that pose significant acute and chronic dangers to militarycombatants as potential warfare agents. There are many examples of mycotoxins, some more acutely potent than others. Mycotoxin is classified as ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: LIFE SERVICES L.L.C. Topic: 101
DESCRIPTION provided by applicant For this Phase I STTR proposal the investigators plan to develop the radiofrequency RF coil technology required for high resolution fMRI at T In the absence of a body transmit coil all T head coils must also incorporate a transmitter in addition to the receiver Here we propose a transmit array with up to individual channels combined with a receive a ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: NIA
DESCRIPTION provided by applicant Insomnia of sufficient clinical severity to meet diagnostic criteria is present in approximately of older adults nearly million individuals n the US alone If left untreated it can lead to increased rates of depression cognitive impairment and cardiovascular disease Treatment relies on pharmacotherapy such as sedative hypnotic therapy which is ass ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: KLEIN BUENDEL, INC. Topic: NIMHD
DESCRIPTION provided by applicant African American men experience health disparities across a number of preventable chronic diseases including cardiovascular disease strokes obesity and diabetes Physical activity PA is a modifiable risk factor for these conditions The few PA promotion studies that have included African American men have resulted in successful short term behavior change ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: EXSCIEN CORPORATION Topic: NIDDK
DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: LYST THERAPEUTICS LLC Topic: NHLBI
SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: ImageIQ, Inc. Topic: 300
DESCRIPTION provided by applicant Chronic viral hepatitis is clinically silent until development of cirrhosis and hepatic decompensation Decompensated cirrhosis is a precursor to liver failure and is associated with increased risk of severe esophageal bleeding significant cardiovascular events and death The gold standard for diagnosing cirrhosis is liver biopsy though problems with the pro ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Fluorescence Innovations, Inc. Topic: NIDA
DESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health